أكسيتينيب (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "أكسيتينيب" in Arabic language version.

refsWebsite

Global rank Arabic rank

11web.archive.org

1^st place

7doi.org

2^nd place

5^th place

7nih.gov

4^th place

6^th place

2ascopubs.org

low place

1wikidata.org

43^rd place

2^nd place

1medscape.com

719^th place

243^rd place

1reuters.com

49^th place

57^th place

1genengnews.com

low place

1onclive.com

low place

1cancernetwork.com

low place

5,261^st place

1nature.com

234^th place

251^st place

1fda.gov

447^th place

393^rd place

1spandidos-publications.com

low place

ascopubs.org

Rini, B؛ Rixe, O؛ Bukowski, R؛ Michaelson, MD؛ Wilding, G؛ Hudes, G؛ Bolte, O؛ Steinfeldt, H؛ Reich, SD؛ Motzer, R (يونيو 2005). "AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)". Journal of Clinical Oncology ASCO Annual Meeting Proceedings. ج. 23 ع. 16S: 4509. مؤرشف من الأصل في 2019-12-08.
Rugo, HS؛ Herbst, RS؛ Liu, G؛ Park, JW؛ Kies, MS؛ Steinfeldt, HM؛ Pithavala, YK؛ Reich, SD؛ Freddo, JL؛ Wilding, G (أغسطس 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology. ج. 23 ع. 24: 5474–83. DOI:10.1200/JCO.2005.04.192. PMID:16027439. مؤرشف من الأصل (PDF) في 2020-04-27.

cancernetwork.com

ALK1/VEGF Combo Active in Advanced RCC. نسخة محفوظة 02 فبراير 2017 على موقع واي باك مشين.

doi.org

Drug Indications Extracted from FAERS، DOI:10.5281/ZENODO.1435999، QID:Q56863002
Wilmes, LJ؛ Pallavicini, MG؛ Fleming, LM؛ Gibbs, J؛ Wang, D؛ Li, KL؛ Partridge, SC؛ Henry, RG؛ Shalinsky, DR؛ Hu-Lowe, D؛ Park, JW؛ McShane, TM؛ Lu, Y؛ Brasch, RC؛ Hylton, NM (أبريل 2007). "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging". Magnetic Resonance Imaging. ج. 25 ع. 3: 319–27. DOI:10.1016/j.mri.2006.09.041. PMID:17371720.
Rugo, HS؛ Herbst, RS؛ Liu, G؛ Park, JW؛ Kies, MS؛ Steinfeldt, HM؛ Pithavala, YK؛ Reich, SD؛ Freddo, JL؛ Wilding, G (أغسطس 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology. ج. 23 ع. 24: 5474–83. DOI:10.1200/JCO.2005.04.192. PMID:16027439. مؤرشف من الأصل (PDF) في 2020-04-27.
Spano, JP؛ Chodkiewicz, C؛ Maurel, J؛ Wong, R؛ Wasan, H؛ Barone, C؛ Létourneau, R؛ Bajetta, E؛ Pithavala, Y (يونيو 2008). "Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study". Lancet. ج. 371 ع. 9630: 2101–2108. DOI:10.1016/S0140-6736(08)60661-3. PMID:18514303.
Tea Pemovska؛ Eric Johnson؛ Mika Kontro؛ Gretchen A. Repasky؛ Jeffrey Chen؛ Peter Wells؛ Ciarán N. Cronin؛ Michele McTigue؛ Olli Kallioniemi. "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation". Nature. ج. 519: 102–105. DOI:10.1038/nature14119. PMID:25686603. مؤرشف من الأصل في 2019-12-08.
Escudier, B؛ Gore, M. "Axitinib for the Management of Metastatic Renal Cell Carcinoma" (PDF). Drugs in R&d. ج. 11 ع. 2: 113–126. DOI:10.2165/11591240-000000000-00000. PMID:21679004. مؤرشف من الأصل (PDF) في 2019-12-16.
Zhang Y (يناير 2014). "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". J Mol Med Rep. ج. 9 ع. 1: 83–90. DOI:10.3892/mmr.2013.1781. PMID:24213221. مؤرشف من الأصل في 2018-09-20.

fda.gov

accessdata.fda.gov

"FDA Prescribing Information" (PDF). 30 يناير 2012. مؤرشف من الأصل (PDF) في 2017-02-25.

genengnews.com

"Pfizer's Phase III Trial in mRCC Turns Up Positive Results". 19 نوفمبر 2010. مؤرشف من الأصل في 2018-02-20.

medscape.com

reference.medscape.com

"Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. مؤرشف من الأصل في 2018-07-05. اطلع عليه بتاريخ 2014-01-25.

nature.com

Tea Pemovska؛ Eric Johnson؛ Mika Kontro؛ Gretchen A. Repasky؛ Jeffrey Chen؛ Peter Wells؛ Ciarán N. Cronin؛ Michele McTigue؛ Olli Kallioniemi. "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation". Nature. ج. 519: 102–105. DOI:10.1038/nature14119. PMID:25686603. مؤرشف من الأصل في 2019-12-08.

nih.gov

pubmed.ncbi.nlm.nih.gov

Wilmes, LJ؛ Pallavicini, MG؛ Fleming, LM؛ Gibbs, J؛ Wang, D؛ Li, KL؛ Partridge, SC؛ Henry, RG؛ Shalinsky, DR؛ Hu-Lowe, D؛ Park, JW؛ McShane, TM؛ Lu, Y؛ Brasch, RC؛ Hylton, NM (أبريل 2007). "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging". Magnetic Resonance Imaging. ج. 25 ع. 3: 319–27. DOI:10.1016/j.mri.2006.09.041. PMID:17371720.
Rugo, HS؛ Herbst, RS؛ Liu, G؛ Park, JW؛ Kies, MS؛ Steinfeldt, HM؛ Pithavala, YK؛ Reich, SD؛ Freddo, JL؛ Wilding, G (أغسطس 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology. ج. 23 ع. 24: 5474–83. DOI:10.1200/JCO.2005.04.192. PMID:16027439. مؤرشف من الأصل (PDF) في 2020-04-27.
Spano, JP؛ Chodkiewicz, C؛ Maurel, J؛ Wong, R؛ Wasan, H؛ Barone, C؛ Létourneau, R؛ Bajetta, E؛ Pithavala, Y (يونيو 2008). "Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study". Lancet. ج. 371 ع. 9630: 2101–2108. DOI:10.1016/S0140-6736(08)60661-3. PMID:18514303.
Tea Pemovska؛ Eric Johnson؛ Mika Kontro؛ Gretchen A. Repasky؛ Jeffrey Chen؛ Peter Wells؛ Ciarán N. Cronin؛ Michele McTigue؛ Olli Kallioniemi. "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation". Nature. ج. 519: 102–105. DOI:10.1038/nature14119. PMID:25686603. مؤرشف من الأصل في 2019-12-08.
Escudier, B؛ Gore, M. "Axitinib for the Management of Metastatic Renal Cell Carcinoma" (PDF). Drugs in R&d. ج. 11 ع. 2: 113–126. DOI:10.2165/11591240-000000000-00000. PMID:21679004. مؤرشف من الأصل (PDF) في 2019-12-16.
Zhang Y (يناير 2014). "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". J Mol Med Rep. ج. 9 ع. 1: 83–90. DOI:10.3892/mmr.2013.1781. PMID:24213221. مؤرشف من الأصل في 2018-09-20.

ncbi.nlm.nih.gov

Escudier, B؛ Gore, M. "Axitinib for the Management of Metastatic Renal Cell Carcinoma" (PDF). Drugs in R&d. ج. 11 ع. 2: 113–126. DOI:10.2165/11591240-000000000-00000. PMID:21679004. مؤرشف من الأصل (PDF) في 2019-12-16.

onclive.com

"ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma". 7 ديسمبر 2011. مؤرشف من الأصل في 2018-04-05.

reuters.com

"Pfizer pancreatic cancer drug fails, trial halted". Reuters. 30 يناير 2009. مؤرشف من الأصل في 2009-02-14.

spandidos-publications.com

Zhang Y (يناير 2014). "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". J Mol Med Rep. ج. 9 ع. 1: 83–90. DOI:10.3892/mmr.2013.1781. PMID:24213221. مؤرشف من الأصل في 2018-09-20.

web.archive.org

"Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. مؤرشف من الأصل في 2018-07-05. اطلع عليه بتاريخ 2014-01-25.
Rini, B؛ Rixe, O؛ Bukowski, R؛ Michaelson, MD؛ Wilding, G؛ Hudes, G؛ Bolte, O؛ Steinfeldt, H؛ Reich, SD؛ Motzer, R (يونيو 2005). "AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)". Journal of Clinical Oncology ASCO Annual Meeting Proceedings. ج. 23 ع. 16S: 4509. مؤرشف من الأصل في 2019-12-08.
Rugo, HS؛ Herbst, RS؛ Liu, G؛ Park, JW؛ Kies, MS؛ Steinfeldt, HM؛ Pithavala, YK؛ Reich, SD؛ Freddo, JL؛ Wilding, G (أغسطس 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results". Journal of Clinical Oncology. ج. 23 ع. 24: 5474–83. DOI:10.1200/JCO.2005.04.192. PMID:16027439. مؤرشف من الأصل (PDF) في 2020-04-27.
"Pfizer pancreatic cancer drug fails, trial halted". Reuters. 30 يناير 2009. مؤرشف من الأصل في 2009-02-14.
"Pfizer's Phase III Trial in mRCC Turns Up Positive Results". 19 نوفمبر 2010. مؤرشف من الأصل في 2018-02-20.
"ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma". 7 ديسمبر 2011. مؤرشف من الأصل في 2018-04-05.
ALK1/VEGF Combo Active in Advanced RCC. نسخة محفوظة 02 فبراير 2017 على موقع واي باك مشين.
Tea Pemovska؛ Eric Johnson؛ Mika Kontro؛ Gretchen A. Repasky؛ Jeffrey Chen؛ Peter Wells؛ Ciarán N. Cronin؛ Michele McTigue؛ Olli Kallioniemi. "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation". Nature. ج. 519: 102–105. DOI:10.1038/nature14119. PMID:25686603. مؤرشف من الأصل في 2019-12-08.
"FDA Prescribing Information" (PDF). 30 يناير 2012. مؤرشف من الأصل (PDF) في 2017-02-25.
Escudier, B؛ Gore, M. "Axitinib for the Management of Metastatic Renal Cell Carcinoma" (PDF). Drugs in R&d. ج. 11 ع. 2: 113–126. DOI:10.2165/11591240-000000000-00000. PMID:21679004. مؤرشف من الأصل (PDF) في 2019-12-16.
Zhang Y (يناير 2014). "Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways". J Mol Med Rep. ج. 9 ع. 1: 83–90. DOI:10.3892/mmr.2013.1781. PMID:24213221. مؤرشف من الأصل في 2018-09-20.

wikidata.org

Drug Indications Extracted from FAERS، DOI:10.5281/ZENODO.1435999، QID:Q56863002